TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

27 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

22 studies on the map

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis — Northwestern Memorial Hospital, ChicagoEffect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD — Washington DC Veterans Affairs Medical Center (688), Washington D.C.Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis — MGH Institute of Health Professions, BostonA Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease — Barrow Neurological Institute, PhoenixMechanism of SGLT2 Inhibition in the Kidney — University of Michigan, Ann ArborHome Based Infusions for Ocrelizumab — Amerita, CentennialCortical Electrophysiology of Response Inhibition in Parkinson's Disease — Emory University Hospital, AtlantaProspective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — University of Colorado Anschutz Medical Campus, AuroraStudy of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis — Johns Hopkins University, BaltimoreGlucose Consumption in MS Using [F-18]FDG-PET — Brigham & Women's Hospital, BostonSilodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis — Atlantic Health, MorristownBOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease — Cleveland Clinic, ClevelandPimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis — Southern Arizona VA Health Care System, Tucson, AZ, TucsonOcrelizumab Discontinuation in Relapsing Multiple Sclerosis — Yale School of Medicine, New HavenElucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia — Virginia Commonwealth University, RichmondEmpagliflozin Treatment in Kidney Transplant Recipients — Edward Hines Jr. VA Hospital, Hines, IL, HinesPersonalized Real-Time DBS and PD Mechanisms — Cleveland Clinic, ClevelandPioglitazone to Reduce Sympathetic Overactivity in CKD Patients — University of Texas at Arlington, ArlingtonOral Iron in Children With Chronic Kidney Disease — Weill Cornell Medicine / New York Presbyterian Hospital, New YorkCharacterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases — Vanderbilt University Medical Center, NashvilleComparing Antipsychotic Medications in LBD Over Time — University Health System, San AntonioSafety of Short-course of NSAIDs in Pediatric Patients With CKD — Children's Hospital Colorado, Aurora